Ca++ and Na+ channels involved in neuronal cell death. Protection by flunarizine.
Flunarizine, a class IV Ca++ antagonist non-selective for slow Ca++ channels, has been shown to be beneficial in the prophylactic treatment of migraine, the treatment of vertigo, and as add-on treatment in therapy-resistant forms of epilepsy. Flunarizine protects the brain against functional and/or structural neuronal damage in various animal models of cerebral ischemia. In addition to its cerebrovascular effect, flunarizine has also direct neuroprotective actions. New data have emerged on flunarizine with regard to Ca++ and Na+ channels in neuronal cells. There are several possible mechanisms involved in the mode of action of flunarizine. Flunarizine may block Ca++ and Na+ channels, both of which may flux Ca++ as well as Na+. A decrease in Ca++ influx may prevent further release of glutamate, and activation of NMDA receptor gated Ca++ channels at physiological pH. A decrease in Na+ influx may prevent cytotoxicity secondary to a large gain in intracellular Ca++, by reverse operation of the Na+/Ca++ exchanger. This mechanism may be important when the glycolytic rate is increased with concomitant acidosis, and phospholipids are broken down as occurs typically during ischemia. Given the complexity of biochemical events leading to cell death, blocking exclusively one channel subtype is not likely to yield sufficient protection. Hence, it may be useful to develop anti-ischemic compounds which act on a series of pathways involved in Ca++ overload, rather than selectively block one such channel.
Pauwels
P J
PJ
Department of Biochemical Pharmacology, Janssen Research Foundation, Beerse, Belgium.
Leysen
J E
JE
Janssen
P A
PA
D000818:Animals; D001921:Brain / Q000166:cytology / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D015220:Calcium Channels / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D005444:Flunarizine / Q000494:pharmacology*; D008564:Membrane Potentials / Q000187:drug effects; D009474:Neurons / Q000187:drug effects*; D012964:Sodium / Q000378:metabolism; D015222:Sodium Channels / Q000187:drug effects*; D014701:Veratridine / Q000494:pharmacology
D015220:Calcium Channels; D015222:Sodium Channels; D014701:Veratridine; D012964:Sodium; D005444:Flunarizine; D002118:Calcium